Biodexa Pharmaceuticals (BDRX) announced the appointment of Precision for Medicine as the clinical research organization, CRO, to conduct the European component of the upcoming registrational Phase 3 study of eRapa in FAP. The U.S. component of the study will be conducted by LumaBridge, based in San Antonio, Texas. The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo. It is expected the study will be conducted in approximately 30 clinical sites across the US and Europe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals Secures U.S. Patent for eRapa, Plans Phase 3 Study
- Biodexa Pharmaceuticals announces allowance of U.S. patent covering eRapa
- Biotech Alert: Searches spiking for these stocks today
- Biodexa Pharmaceuticals to Present at Emerging Growth Conference
- Biodexa Pharmaceuticals receives Fast Track designation for eRapa
Questions or Comments about the article? Write to editor@tipranks.com